StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Factor scoring needs Finnhub-supplied fundamentals — Finnhub returned no fundamental metrics for this ticker. Common for ETFs, foreign filers without US listing depth, recent IPOs, and thinly-traded OTC names.
6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-11 | $3.42 | $3.52 | +2.92% | 0.0M |
| 05-12 | $3.52 | $3.54 | +0.57% | 0.0M |
| 05-13 | $3.71 | $3.51 | -5.33% | 0.0M |
| 05-14 | $3.39 | $3.40 | +0.29% | 0.0M |
| 05-15 | $3.31 | $3.37 | +1.81% | 0.0M |
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
No sell-side coverage available for PLUR.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Metric | Annual 2025 2025-06-30 | Annual 2024 2024-06-30 | Q1 2019 2019-03-31 | Q4 2018 2018-12-31 |
|---|---|---|---|---|
Revenue | $1.34M | $326.00K | $250.00K | $250.00K |
Operating Income | $-22.18M | $-22.16M | $-27.60M | $-17.30M |
Net Income | $-22.58M | $-20.89M | $-27.55M | $-17.47M |
EPS (Diluted) | $-3.56 | $-3.99 | Not available | Not available |
Total Assets | $38.68M | $39.53M | $18.73M | $24.30M |
Total Liabilities | Not available | Not available | Not available | Not available |
Cash & Equivalents | $5.89M | $6.78M | $9.54M | $6.80M |
Free Cash Flow OCF − CapEx | $-19.83M | $-18.34M | $-23.00M | $-16.97M |
Shares Outstanding | 7.89M | 5.41M | 119.32M | 116.81M |
Fundamentals not available for PLUR.
No fundamental metrics available yet for this ticker — common for ETFs, foreign issuers without US listing depth, very recent IPOs, or thinly-traded OTC names. The Financials tab pulls from SEC EDGAR directly and may still have data.
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.